

ProteoTech to Present at 2009 International Conference on Alzheimer's Disease – Vienna, Austria, July 11-16, 2009

Kirkland, WA, July, 2009 - ProteoTech Inc. announced today that Dr. Qubai Hu, Director of Molecular Biology will present at the 2009 International Conference for Alzheimer's Disease, to be held in Vienna, Austria, July 11-16, 2009.

Dr. Hu will present on Tuesday, July 14 during the "Amyloid-based therapeutic Strategies" poster session. Dr. Hu's presentation is entitled:

"EXEBRYL-1[®]: A Novel Small Molecule Drug that Reduces Amyloid Plaque Load and Improves Memory Enters Human Clinical Trials."

EXEBRYL-1[®] is a small molecule compound that has been shown to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid protein, as well as amyloid plaques, found in Alzheimer's brains of disease victims.

About ProteoTech: ProteoTech is a private drug development company founded in 1996 located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. Besides EXEBRYL-1[®] for Alzheimer's disease treatment, the Company is also in late stage pre-clinical development of *Synucleone*[™] for the treatment of Parkinson's disease, Systebryl[™] for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called **PeptiClere**[™] for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com.